NBIX - CIK 0000914475
NEUROCRINE BIOSCIENCES INC (NBIX) reported revenue of $2.86B for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $2.86B | +21.4% |
| FY 2024 | $2.36B | +24.8% |
| FY 2023 | $1.89B | +26.8% |
| FY 2022 | $1.49B | +31.3% |
| FY 2021 | $1.13B | +8.4% |
| FY 2020 | $1.05B | +32.7% |
| FY 2019 | $788.10M | +74.7% |
| FY 2018 | $451.20M | +179.2% |
| FY 2017 |
NEUROCRINE BIOSCIENCES INC (NBIX) reported revenue of $2.86B for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, NEUROCRINE BIOSCIENCES INC's revenue grew from $77.41M to $2.86B.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $161.63M |
| +977.5% |
| FY 2016 | $15.00M | -24.1% |
| FY 2015 | $19.77M | - |
| FY 2014 | $0.00 | -100.0% |
| FY 2013 | $2.92M | -94.5% |
| FY 2012 | $53.14M | -31.4% |
| FY 2011 | $77.41M | - |